Context: The increasing recognition that women who are unable or unwilling
to discuss or use condoms with their sexual partners need female-controlled
methods for preventing sexually transmitted diseases (STDs), including HIV
, has led to considerable focus on the development of vaginal microbicides.
While many such products are being tested for safety and effectiveness, cl
inical trials generally overlook another key factor in a product's impact o
n infection rates-its acceptability to users.
Methods: A Phase I clinical trial of a microbicidal gel included an assessm
ent of the product's acceptability among 27 low-risk participants. Informat
ion on acceptability was gathered from structured interviews, participants'
daily diaries and unstructured exit interviews.
Results: Participants reported only minor side effects of product use, such
as itching, burning and difficulty urinating; two women developed candida
infections while participating in the study. None of the side effects could
be conclusively linked to use of the gel Some women noted product discharg
e and messiness as drawbacks of the method, but this experience varied acco
rding to how often the women applied the gel. For example, one-third of tho
se who used it once daily said that at least some of the time, it was too "
wet or drippy," compared with two-thirds of women who inserted the gel twic
e a day. However, participants considered these "nuisance factors" that cou
ld be outweighed by the potential protective characteristics of the product
. The majority reported that they would use the product if it were availabl
e and proven efficacious, and if they perceived that they were at risk of S
TD infection.
Conclusions: Additional testing of this product is urgently needed. Further
more, as other products approach Phase I testing, acceptability assessments
should be a key component of clinical trials.